Cargando…
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial
This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and once-daily repeat doses of vilanterol 25 µg in children aged 5–11 years. Twenty-eight children wi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467260/ https://www.ncbi.nlm.nih.gov/pubmed/26097789 http://dx.doi.org/10.1002/cpdd.92 |
_version_ | 1782376353315684352 |
---|---|
author | Oliver, Amanda VanBuren, Sandi Allen, Ann Hamilton, Melanie Tombs, Lee Kempsford, Rodger Qaqundah, Paul |
author_facet | Oliver, Amanda VanBuren, Sandi Allen, Ann Hamilton, Melanie Tombs, Lee Kempsford, Rodger Qaqundah, Paul |
author_sort | Oliver, Amanda |
collection | PubMed |
description | This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and once-daily repeat doses of vilanterol 25 µg in children aged 5–11 years. Twenty-eight children with persistent asthma received a single inhaled dose of vilanterol 25 µg or placebo via the ELLIPTA™ dry powder inhaler (DPI) on Day 1, followed 7 days later by once-daily treatment for 7 days. Nine (33%) subjects reported adverse events (AEs) with vilanterol 25 µg and 6 (23%) with placebo. No serious or drug-related AEs were reported; 3 subjects experienced upper respiratory tract infection (URTI) with vilanterol 25 µg versus none with placebo. Similar pharmacokinetic profiles of vilanterol 25 µg were observed irrespective of age or gender. No clinically relevant changes in heart rate, Fridericia's correction (QTcF), maximum glucose or minimum potassium parameters were observed during treatment with vilanterol 25 µg compared with placebo treatment. Vilanterol was well-tolerated and no long-acting ß(2)-agonist (LABA)-mediated AEs were observed. The pharmacokinetic profile of vilanterol 25 µg suggests exposure is similar regardless of age or gender in a pediatric population aged 5–11 years. |
format | Online Article Text |
id | pubmed-4467260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44672602015-06-17 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial Oliver, Amanda VanBuren, Sandi Allen, Ann Hamilton, Melanie Tombs, Lee Kempsford, Rodger Qaqundah, Paul Clin Pharmacol Drug Dev Original Articles This multi-center, randomized, double-blind, placebo-controlled, two-way crossover study was designed to characterize the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of single and once-daily repeat doses of vilanterol 25 µg in children aged 5–11 years. Twenty-eight children with persistent asthma received a single inhaled dose of vilanterol 25 µg or placebo via the ELLIPTA™ dry powder inhaler (DPI) on Day 1, followed 7 days later by once-daily treatment for 7 days. Nine (33%) subjects reported adverse events (AEs) with vilanterol 25 µg and 6 (23%) with placebo. No serious or drug-related AEs were reported; 3 subjects experienced upper respiratory tract infection (URTI) with vilanterol 25 µg versus none with placebo. Similar pharmacokinetic profiles of vilanterol 25 µg were observed irrespective of age or gender. No clinically relevant changes in heart rate, Fridericia's correction (QTcF), maximum glucose or minimum potassium parameters were observed during treatment with vilanterol 25 µg compared with placebo treatment. Vilanterol was well-tolerated and no long-acting ß(2)-agonist (LABA)-mediated AEs were observed. The pharmacokinetic profile of vilanterol 25 µg suggests exposure is similar regardless of age or gender in a pediatric population aged 5–11 years. BlackWell Publishing Ltd 2014-05 2014-02-06 /pmc/articles/PMC4467260/ /pubmed/26097789 http://dx.doi.org/10.1002/cpdd.92 Text en © 2014 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Oliver, Amanda VanBuren, Sandi Allen, Ann Hamilton, Melanie Tombs, Lee Kempsford, Rodger Qaqundah, Paul Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title_full | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title_fullStr | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title_full_unstemmed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title_short | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5–11 Years with Persistent Asthma: A Randomized Trial |
title_sort | safety, tolerability, pharmacokinetics, and pharmacodynamics of vilanterol, a novel inhaled long-acting β-agonist, in children aged 5–11 years with persistent asthma: a randomized trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467260/ https://www.ncbi.nlm.nih.gov/pubmed/26097789 http://dx.doi.org/10.1002/cpdd.92 |
work_keys_str_mv | AT oliveramanda safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT vanburensandi safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT allenann safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT hamiltonmelanie safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT tombslee safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT kempsfordrodger safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial AT qaqundahpaul safetytolerabilitypharmacokineticsandpharmacodynamicsofvilanterolanovelinhaledlongactingbagonistinchildrenaged511yearswithpersistentasthmaarandomizedtrial |